DelveInsight’s, “Fragile X Syndrome Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Fragile X Syndrome pipeline landscape. It covers the Fragile X Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Fragile X Syndrome Pipeline Report
- DelveInsight’s Fragile X Syndrome pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Fragile X Syndrome treatment.
- The leading companies working in the Fragile X Syndrome Market include Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.
- Promising Fragile X Syndrome Pipeline Therapies in the various stages of development include Psilocybin, 1.5 mg, MG01CI extended-release tablet, Zatolmilast/ BPN14770, ZYN002 – transdermal gel, arbaclofen, AFQ056, Ganaxolone, STX209, and others.
- In February 2023, Tetra Discovery Partners announced a study of Phase 3 Clinical Trials for Zatolmilast/ BPN14770. This is an open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301(in adult males) and Study BPN14770-CNS-204 (in adolescent males).
- In May 2023, Nova Mentis Life Sciences Corp. announced a study of Phase 2 Clinical Trials for Psilocybin, 1.5 mg. The overall objective of this study is to assess the feasibility of low-dose psilocybin as a therapeutic option for individuals living with FXS and to improve diagnostic parameters of FXS, as well as therapeutic responses with the use of biomarkers.
Request a sample and discover the recent advances in Fragile X Syndrome Treatment Drugs @ Fragile X Syndrome Pipeline Report
The Fragile X Syndrome pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Fragile X Syndrome drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Fragile X Syndrome clinical trial landscape.
Fragile X Syndrome Overview
Fragile X syndrome (FXS) is a genetic disorder. FXS is caused by changes in a gene that scientists called the fragile X mental retardation 1 (FMR1) gene when it was first discovered. The FMR1 gene usually makes a protein called fragile X mental retardation protein (FMRP). FMRP is needed for normal brain development.
Find out more about Fragile X Syndrome Treatment Drugs @ Drugs for Fragile X Syndrome Treatment
Fragile X Syndrome Emerging Drugs Profile
- Zatolmilast: Tetra Discovery Partners
- Zygel: Zynerba Pharmaceuticals
- Pridopidine: Prilenia Therapeutics
Fragile X Syndrome Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Fragile X Syndrome. The Fragile X Syndrome companies which have their Fragile X Syndrome drug candidates in the most advanced stage, i.e. Phase III include Zynerba Pharmaceuticals and others.
Learn more about the emerging Fragile X Syndrome Pipeline Therapies @ Fragile X Syndrome Clinical Trials Assessment
Scope of the Fragile X Syndrome Pipeline Report
- Coverage- Global
- Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Fragile X Syndrome Companies- Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.
- Fragile X Syndrome Pipeline Therapies- Psilocybin, 1.5 mg, MG01CI extended-release tablet, Zatolmilast/ BPN14770, ZYN002 – transdermal gel, arbaclofen, AFQ056, Ganaxolone, STX209, and others.
Dive deep into rich insights for new drugs for Fragile X Syndrome Treatment, Visit @ Fragile X Syndrome Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Fragile X Syndrome: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Fragile X Syndrome– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Fragile X Syndrome Collaboration Deals
- Late Stage Products (Phase III)
- Zatolmilast: Tetra Discovery Partners
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- HLX-0201: Healx
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Pridopidine: Prilenia Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Fragile X Syndrome Key Companies
- Fragile X Syndrome Key Products
- Fragile X Syndrome- Unmet Needs
- Fragile X Syndrome- Market Drivers and Barriers
- Fragile X Syndrome- Future Perspectives and Conclusion
- Fragile X Syndrome Analyst Views
- Fragile X Syndrome Key Companies
- Appendix
For further information on the Fragile X Syndrome Pipeline therapeutics, reach out to Fragile X Syndrome Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting